Phase 2 OME Clinical Trials
722 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 722 trials
Recruiting
Phase 1Phase 2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 2
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
University of Washington30 enrolled1 locationNCT06738368
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06308588
Recruiting
Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial Cancer
Canadian Cancer Trials Group393 enrolled108 locationsNCT05640999
Recruiting
Phase 2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 2
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Myelodysplastic Syndrome
National Cancer Institute (NCI)54 enrolled140 locationsNCT06577441
Recruiting
Phase 2Phase 3
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
KSHV Inflammatory Cytokine Syndrome (KICS)KSHVHHV-8
National Cancer Institute (NCI)140 enrolled1 locationNCT01419561
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting
Phase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled29 locationsNCT05919264
Recruiting
Phase 2
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting
Phase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
Acute Respiratory Distress Syndrome (ARDS)ARDSAcute Respiratory Distress Syndrome+1 more
PPD Development, LP200 enrolled40 locationsNCT06701669
Recruiting
Phase 2
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Noonan Syndrome
BioMarin Pharmaceutical30 enrolled36 locationsNCT06668805
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Acute Respiratory Distress Syndrome (ARDS)ARDSAcute Respiratory Distress Syndrome+1 more
PPD Development, LP200 enrolled40 locationsNCT06701656
Recruiting
Phase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167